To the best of our knowledge, the present study is the first to investigate the effect of statin therapy on hepcidin and hemojuvelin serum concentration, iron utilization and metabolism in ESA naive patients with moderate to advanced CKD. This evidence concerns the gene HAMP and chronic kidney disease.